三維天地(301159.SZ):199.925萬股首發前已發行股份將於7月7日解禁
格隆匯7月5日丨三維天地(301159.SZ)公佈首次公開發行前已發行部分股份上市流通提示性公吿,本次解除限售的股份為公司首次公開發行前已發行的部分股份,限售期為自公司首次公開發行並上市之日起12個月,上市後六個月期末(即2022年7月7日)公司股票收盤價低於發行價30.28元/股,觸發相關股東承諾的履行條件,鎖定期延長6個月至2023年7月6日。本次解除股份限售的股東共計2名,本次解除限售的股份數量為199.925萬股,佔公司股本總額的2.58%。本次解除限售股份的上市流通日期為2023年7月7日(星期五)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.